This article is more than 5 years old. Information may no longer be current.
Research updates for Blood Cancer Awareness Month
Click Here to Manage Email Alerts
The Leukemia & Lymphoma Society has deemed September Blood Cancer Awareness Month.
Blood cancers are the third leading cause of cancer deaths in the U.S., with a new diagnosis approximately every 3 minutes, according to the society.
To mark this month, HemOnc Today highlighted important research updates for the treatment of leukemia, lymphoma, myeloma and myeloproliferative neoplasms.
Ivosidenib (Tibsovo, Agios Pharmaceuticals) — an oral, targeted, small molecule inhibitor of mutant IDH1 — induced durable remissions among patients with IDH1-mutated relapsed or refractory acute myeloid leukemia. READ MORE.
Additionally, the FDA approved ivosidenib for this indication. READ MORE.
Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments. READ MORE.
Gene editing may enhance CAR T-cell therapy for hematologic malignancies, according to research from Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. READ MORE.
Patients with previously untreated follicular lymphoma demonstrated improved PFS with the addition of obinutuzumab (Gazyva, Genentech) to chemotherapy. However, safety differed among the chemotherapy regimens. READ MORE.
Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral chemotherapy, thereby increasing their chances of survival. READ MORE.
The use of interim PET accurately predicted survival among patients with aggressive lymphomas treated with rituximab (Rituxan; Genentech, Biogen) plus CHOP. READ MORE.
Two methods of measuring multiple myeloma DNA in blood samples provided highly detailed genetic information that appeared consistent with results of bone marrow biopsy. READ MORE.
Patients who underwent blood or marrow transplantation during childhood remained at greater risk for death up to 25 years later compared with the general population. Still, mortality rates following transplantation have decreased over the past 3 decades. READ MORE.